Pharmacogenomics (PGx) Proton Pump Inhibitors CYP2C19 Test
A targeted pharmacogenomic test evaluating CYP2C19 metabolizer status to optimize proton pump inhibitor prescription and dosing, powered by the Helix Exome+® platform.
6-9 days
≤ 5 minutes
Test Description
Proton pump inhibitors are prescribed to patients with gastroesophageal reflux disease (GERD), peptic ulcer disease and other conditions related to dysfunctional gastric acid secretion. Certain CYP2C19 metabolizer types may reduce efficacy of PPIs, while others may lead to increased risk for adverse events.
Patients for whom omeprazole, lansoprazole, pantoprazole, and dexlansoprazole are being considered, have been ineffective or caused side effects.
Have Questions?
Our team is available Monday through Friday, 9am-5pm Pacific Time.
Indications for Testing
Patients for whom omeprazole, lansoprazole, pantoprazole, and dexlansoprazole are being considered, have been ineffective or caused side effects.
Methodology
This test utilizes next-generation sequencing to determine star alleles and metabolizer status for CYP2C19 and is used to determine drug considerations for omeprazole, lansoprazole, pantoprazole, and dexlansoprazole.
Technical Specifications
CYP2C19: *1-*19, *22-*26, *28-*39
Dexlansoprazole, CYP2C19 (PGKB 1A); Lansoprazole, CYP2C19 (PGKB 1A; CPIC A); Omeprazole, CYP2C19 (PGKB 1A; CPIC A); Pantoprazole, CYP2C19 (FDA Section 1; CPIC A)....
Genes Tested
Showing 1 of 1 genes in this panel